City of Hope received nearly $7 million from the Patient-Centered Outcomes Research Institute to study how physical activity affects older adults undergoing lung cancer surgery.
Researchers at Baylor College of Medicine have received a five-year, $5.5 million-plus grant from NCI for research on liver cancer risk factors and prevention, with the goal of reducing the burden of liver cancer in patients with metabolic dysfunction.
In August, the Cancer History Project is highlighting oral histories, and is continuing to conduct oral histories with people who have made important contributions to oncology—along with patients who have shared their stories with us.
Thermo Fisher Scientific is accepting submissions for the fifth round of the Oncomine Clinical Research Grant program.Â
DoD Peer Reviewed Cancer Research Program anticipated funding opportunities for the 2022 fiscal year
The Department of Defense Peer Reviewed Cancer Research Program anticipates several funding opportunities for FY22.Â
The phase III IMscin001 study evaluating a subcutaneous formulation of Tecentriq (atezolizumab) showed non-inferior levels of Tecentriq in the blood, when injected subcutaneously, compared with intravenous infusion.
Thermo Fisher Scientific has launched a next-generation sequencing-based assay for research in myeloid measurable residual disease.Â
Lynparza (olaparib) was approved by the European Commission as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2 mutations (gBRCAm), who have HER2-negative, high-risk, early-stage breast cancer previously treated with neoadjuvant or adjuvant chemotherapy.
The University of Texas MD Anderson Cancer Center and TransCode Therapeutics Inc. form an alliance to advance TransCode’s pipeline of RNA-targeted oncology therapeutic and diagnostic candidates.
Poseida Therapeutics Inc. entered into a collaboration and license agreement with Roche to develop allogeneic CAR T-cell therapies directed to hematologic malignancies.Â
